Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy
NCT06393465
·
clinicaltrials.gov ↗
COMPLETED
Status
50
Enrollment
INDUSTRY
Sponsor class
Conditions
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Interventions
DRUG:
Tafamidis
Sponsor
Pfizer